Question 1

What are the specific goals of this study regarding brain activity?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) clinical trial (NCT00934466). Contact the study team or your healthcare provider for specific answers.

Question 2

How might the results of this trial impact future treatments for schizophrenia?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) clinical trial (NCT00934466). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the possible side effects of MK2637 and dextromethorphan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) clinical trial (NCT00934466). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my participation be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) clinical trial (NCT00934466). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the treatment visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) clinical trial (NCT00934466). Contact the study team or your healthcare provider for specific answers.

What this study is about